"We are honored to welcome such esteemed colleagues to our new , MD, Chief Scientific Officer at ACT, "The Company will benefit greatly from their new perspectives and diversity of experience and together they bring extensive expertise in cell biology, clinical translation, and the broader field of regenerative medicine. Together with added "ACT is at the forefront of regenerative medicine and plans to initiate phase 2 clinical trials for the treatment of Stargardt's macular degeneration and age-related macular degeneration .
http://ift.tt/1pRe3XR
http://ift.tt/1pRe3XR
No comments:
Post a Comment